Table 1.
Baseline Characteristics of Study Population
| Characteristic | All Participants (N=99) | Index Cases (N=33) | Contacts (N=66) |
|---|---|---|---|
| Age (Median, Min-Max) | 27 (2–66) | 25 (5–64) | 39 (2–66) |
| Sex assigned at birth (N, %) – | |||
| Male | 44 (48.4) | 14 (43.8) | 30 (50.9) |
| Female | 47 (51.7) | 18 (56.3) | 29 (49.2) |
| Missing | 8 | 1 | 7 |
| Race (N, %) – | |||
| American Indian or Alaskan Native | 10 (11.0) | 3 (9.4) | 7 (11.9) |
| Asian | 2 (2.2) | 1 (3.1) | 1 (1.7) |
| Black or African American | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| White | 79 (86.8) | 28 (87.5) | 51 (86.4) |
| Multiple | 0 | 0 | 0 |
| Prefer Not to Report | 0 | 0 | 0 |
| Other | 0 | 0 | 0 |
| Missing | 8 | 1 | 7 |
| Ethnicity (N, %) – | |||
| Hispanic or Latino / Latinx | 3 (3.3) | 1 (3.1) | 2 (3.4) |
| Not Hispanic or Latino / Latinx | 88 (96.7) | 31 (96.9) | 57 (96.6) |
| Missing | 8 | 1 | 7 |
| Body Mass Index (Median, Min/Max) | 22.9 (14.1–7.2) | 23.0 (16.1–37.1) | 22.7 (14.1–47.2) |
| Missing | 19 | 9 | 10 |
| Medical Conditions (N, %) | |||
| None | 69 (81.2) | 21 (72.4) | 48 (85.7) |
| Cancer | 0 | 0 | 0 |
| Diabetes | 1 (1.2) | 1 (3.5) | 0 |
| Asthma or wheezing | 10 (11.8) | 5 (17.2) | 5 (8.9) |
| COPD/Emphysema | 0 | 0 | 0 |
| High blood pressure | 3 (3.5) | 1 (3.5) | 2 (3.6) |
| Coronary artery disease | 0 | 0 | 0 |
| Congestive heart failure | 0 | 0 | 0 |
| Peripheral artery disease | 0 | 0 | 0 |
| Other* | 2 (2.4) | 1 (3.5) | 1 (1.8) |
| Missing | 14 | 4 | 10 |
| Autoimmune or Immune System Diseases, Any** (N, %) | 7 (8.2) | 1 (3.7) | 6 (10.3) |
| Missing | 14 | 6 | 8 |
| Prior Diagnosis of COVID-19 (N, %) | 9 (9.5) | 1 (3.2) | 8 (12.5) |
| Missing | 4 | 2 | 2 |
| Days between most recent diagnosis and enrollment (Median, Min-Max) | 59 (18–780) | 780 | 57 (18–462) |
| Hospitalized for COVID-19 (N, %) – missing 1 | 0 | 0 | 0 |
| Prior Receipt of a COVID-19 Vaccine (N, %) – missing 2 | 95 (97.9) | 32 (100) | 63 (96.9) |
| Number of doses (Median, Min-Max) | 3 (2–4) | 3 (2–4) | 3 (2–4) |
| Days between most recent COVID-19 vaccination and enrollment (Median, Min-Max) – missing 4 | 165 (1–308) | 165 (48–308) | 165 (1–307) |
| Days between most recent diagnosis OR most recent COVID-19 vaccination (whichever is more recent) and enrollment (Median, Min-Max) | 160 (0–308) | 164.5 (0–308) | 160 (1–307) |
| Missing | 2 | 1 | 1 |
*
Reported by participant: “heart aneurysm” (1); history of stroke (2)
**
Reported by participant: “irritable bowel syndrome, eczema and allergies” (1); “vitiligo” (1); “diverticulosis” (1); “Reynaud’s disease” (1)